



US010485896B2

(12) **United States Patent**
Lebreton

(10) **Patent No.:** **US 10,485,896 B2**

(45) **Date of Patent:** ***Nov. 26, 2019**

(54) **HYALURONIC ACID-BASED GELS
INCLUDING LIDOCAINE**

(71) Applicant: **Allergan Industrie SAS**, Pringy (FR)

(72) Inventor: **Pierre F. Lebreton**, Annecy (FR)

(73) Assignee: **ALLERGAN INDUSTRIE SAS**,
Pringy (FR)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **16/186,448**

(22) Filed: **Nov. 9, 2018**

(65) **Prior Publication Data**

US 2019/0076579 A1 Mar. 14, 2019

Related U.S. Application Data

(63) Continuation of application No. 15/443,080, filed on
Feb. 27, 2017, which is a continuation of application
No. 14/754,504, filed on Jun. 29, 2015, now
abandoned, which is a continuation of application No.
14/242,752, filed on Apr. 1, 2014, now abandoned,
which is a continuation of application No.
13/419,079, filed on Mar. 13, 2012, now Pat. No.
8,822,676, which is a continuation of application No.
12/393,884, filed on Feb. 26, 2009, now Pat. No.
8,357,795.

(60) Provisional application No. 61/085,956, filed on Aug.
4, 2008, provisional application No. 61/087,934, filed
on Aug. 11, 2008, provisional application No.
61/096,278, filed on Sep. 11, 2008.

(51) **Int. Cl.**

A61L 27/52 (2006.01)
A61K 8/42 (2006.01)
A61K 8/73 (2006.01)
A61L 27/20 (2006.01)
A61L 27/54 (2006.01)
A61Q 19/08 (2006.01)
A61K 31/167 (2006.01)
A61K 31/728 (2006.01)
A61K 9/00 (2006.01)
A61K 9/06 (2006.01)
A61K 47/36 (2006.01)

(52) **U.S. Cl.**

CPC **A61L 27/52** (2013.01); **A61K 8/42**
(2013.01); **A61K 8/735** (2013.01); **A61K**
9/0021 (2013.01); **A61K 9/06** (2013.01); **A61K**
31/167 (2013.01); **A61K 31/728** (2013.01);
A61K 47/36 (2013.01); **A61L 27/20** (2013.01);
A61L 27/54 (2013.01); **A61Q 19/08** (2013.01);
A61L 2300/402 (2013.01); **A61L 2300/602**
(2013.01); **A61L 2400/06** (2013.01)

(58) **Field of Classification Search**

CPC **A61K 8/42**; **A61K 8/735**; **A61K 9/002**;
A61K 9/06; **A61K 31/167**; **A61K 31/728**;
A61L 27/52; **A61L 27/20**; **A61L 27/54**;
A61L 2300/402; **A61L 2300/602**; **A61L**
2400/06; **A61Q 19/08**

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,128,827 A	8/1938	Killian
3,548,056 A	12/1970	Eigen et al.
3,763,009 A	10/1973	Suzuki
3,949,073 A	4/1976	Daniels et al.
4,060,081 A	11/1977	Yannas et al.
4,140,537 A	2/1979	Luck et al.
4,233,360 A	11/1980	Luck et al.
4,273,705 A	6/1981	Kato
4,279,812 A	7/1981	Cioca
4,424,208 A	1/1984	Wallace et al.
4,501,306 A	2/1985	Chu et al.
4,582,640 A	4/1986	Smestad et al.
4,582,865 A	4/1986	Balazs et al.
4,605,691 A	8/1986	Balazs et al.
4,636,524 A	1/1987	Balazs
4,642,117 A	2/1987	Nguyen et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA	949965	6/1974
CA	2416504	1/2002

(Continued)

OTHER PUBLICATIONS

British Pharmacopoeia Lidocaine Safety Data Sheet according to
1907/2006/EC, Article 31 printed Nov. 22, 2013.

(Continued)

Primary Examiner — Ali Soroush

(74) *Attorney, Agent, or Firm* — Nathan S. Smith;
Morgan, Lewis & Bockius LLP

(57) **ABSTRACT**

Disclosed herein are cohesive soft tissue fillers, for example,
dermal and subdermal fillers, based on hyaluronic acids and
pharmaceutically acceptable salts thereof. In one aspect,
hyaluronic acid-based compositions described herein
include a therapeutically effective amount of at least one
anesthetic agent, for example, lidocaine. The present
hyaluronic acid-based compositions including lidocaine
have an enhanced stability and cohesivity, relative to con-
ventional compositions including lidocaine, for example
when subjected to sterilization techniques or when stored for
long periods of time. Methods and processes of preparing
such hyaluronic acid-based compositions are also provided.